Technical Analysis for BBIO - BridgeBio Pharma, Inc.

Grade Last Price % Change Price Change
D 55.51 0.71% 0.39
BBIO closed up 0.71 percent on Monday, April 19, 2021, on 67 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Flat
Historical BBIO trend table...

Date Alert Name Type % Chg
Oversold Stochastic Weakness 0.71%
Oversold Stochastic Weakness 1.02%
Slingshot Bearish Bearish Swing Setup -0.43%
Stochastic Buy Signal Bullish -0.43%
Pocket Pivot Bullish Swing Setup -0.43%
Wide Bands Range Expansion -0.43%
Oversold Stochastic Weakness -0.43%
Slingshot Bearish Bearish Swing Setup 1.67%
Pocket Pivot Bullish Swing Setup 1.67%
Outside Day Range Expansion 1.67%
Older End-of-Day Signals for BBIO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 12 hours ago
60 Minute Opening Range Breakout about 14 hours ago
Rose Above 10 DMA about 14 hours ago
Up 1% about 15 hours ago
10 DMA Resistance about 16 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BridgeBio Pharma, Inc. Description

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Development Organ Systems Anatomy Tyrosine Kinase Tyrosine Kinase Receptors Amyloid Hyperplasia Myopathy Amyloidosis Protein Kinase Inhibitor Cardiomyopathy Fibroblast Growth Factor Receptor Transthyretin Congenital Adrenal Hyperplasia Familial Amyloid Polyneuropathy Polyneuropathy Achondroplasia TTR Amyloidosis

Is BBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 73.5
52 Week Low 26.17
Average Volume 848,192
200-Day Moving Average 48.68
50-Day Moving Average 63.67
20-Day Moving Average 58.63
10-Day Moving Average 55.63
Average True Range 3.21
ADX 18.27
+DI 17.25
-DI 23.18
Chandelier Exit (Long, 3 ATRs ) 61.37
Chandelier Exit (Short, 3 ATRs ) 62.58
Upper Bollinger Band 66.53
Lower Bollinger Band 50.73
Percent B (%b) 0.3
BandWidth 26.95
MACD Line -2.67
MACD Signal Line -2.52
MACD Histogram -0.1497
Fundamentals Value
Market Cap 6.8 Billion
Num Shares 123 Million
EPS -10.90
Price-to-Earnings (P/E) Ratio -5.09
Price-to-Sales 259.96
Price-to-Book 36.28
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 58.24
Resistance 3 (R3) 58.17 57.19 57.79
Resistance 2 (R2) 57.19 56.49 57.23 57.63
Resistance 1 (R1) 56.35 56.07 56.77 56.42 57.48
Pivot Point 55.37 55.37 55.58 55.41 55.37
Support 1 (S1) 54.53 54.67 54.95 54.60 53.54
Support 2 (S2) 53.55 54.25 53.59 53.39
Support 3 (S3) 52.71 53.55 53.24
Support 4 (S4) 52.78